Needham Reiterates Buy on Sarepta Therapeutics, Maintains $185 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Gil Blum reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a $185 price target.
June 23, 2023 | 9:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum reiterated a Buy rating on Sarepta Therapeutics and maintained a $185 price target.
The reiteration of a Buy rating and maintenance of a $185 price target by Needham analyst Gil Blum indicates a positive outlook for Sarepta Therapeutics. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100